Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Veloxis Pharmaceuticals publishes Annual Report 2014


      News provided by

      Veloxis Pharmaceuticals A/S

      Mar 03, 2015, 09:47 ET

      Share this article

      Share this article


      HORSHOLM, Denmark, March 3, 2015 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) ('Veloxis') today published the annual report of Veloxis Pharmaceuticals A/S for the financial year 2014. The annual report has been prepared in accordance with International Financial Reporting Standards as adopted by the EU and additional Danish disclosure requirements for annual reports of listed companies.

      This company announcement should be read in conjunction with Veloxis' annual report 2014 published separately today.

      Full Year 2014 Highlights

      • Filed an action against the FDA, seeking an order requiring FDA to grant final approval to Envarsus® XR.
      • FDA has informed Veloxis of a tentative approval of Envarsus® XR. FDA stated that the final approval of Envarsus® XR will be delayed until expiration of the exclusivity period for Astellas' Astagraf XL®. Veloxis understands that this expiry is anticipated to occur July 19, 2016.
      • The European Commission (EC) has granted marketing authorization for Envarsus® for the prevention of organ rejection in adult kidney and liver transplant patients in the European Union (EU).
      • Once-daily Envarsus® XR (tacrolimus extended-release tablets), demonstrated a lower treatment failure rate in African-Americans compared with twice-daily tacrolimus (Prograf®).
      • Two-year results of the pivotal Phase 3 clinical trial, Study 3002, of Envarsus® XR (tacrolimus extended-release tablets) in de novo kidney transplant patients continued to demonstrate non-inferiority compared to tacrolimus capsules (Prograf®; Astellas Pharma).
      • The FDA has accepted for standard review the company's New Drug Application (NDA) for Envarsus® for the prevention of organ rejection in adult kidney transplant patients.
      • United States Patent and Trademark Office had issued a Notice of Allowance for U.S. Application Serial Number 13/167,420, a patent which covers the diurnal-independent administration of Envarsus®.
      • During 2014, Veloxis recognized revenue from deferred upfront, milestone payments and commercial sales of DKK 123.4 million compared to DKK 38.2 million in 2013.
      • Sales and marketing costs amounted to DKK 41.3 million in 2014. This reflects the hiring and building of the marketing and sales infrastructure.
      • Research and development costs decreased by DKK 56.4 million, or by 38.5%, from DKK 146.5 million in 2013 to DKK 90.1 million in 2014. Research and development costs are mainly attributable to the phase III trial in Envarsus® (de novo patients, Study 3002). The reduction in cost is associated with the overall reduction in study activity as some studies have now been completed.
      • Administrative expenses increased from DKK 27.8 million in 2013 to DKK 47.4 million in 2014. The increase in cost is mainly attributable to legal fees in connection with legal actions against the FDA.
      • During 2014, Veloxis recognized DKK 36.3 million in net loss compared to DKK 139.3 million in 2013. The net loss is in line with management's expectations for 2014 as reported on 12 November 2014 in connection with the third quarter interim report, which projected a net loss of DKK 20 - 50 million.
      • As per 31 December 2014, the balance sheet reflects cash and cash equivalents of DKK 270.4 million compared to DKK 328.7 million as per 31 December 2013. The decrease in cash position reflects the changes in operating activities in 2014. The cash position is in line with management's expectations for 2014, which projected a cash position at the end of 2014 of DKK 255 - 285 million.

      Conference Call
      On 3 March, 2015, Veloxis' Management will host a conference call, at 4:00 PM CET (Denmark); 3:00 PM GMT (London), 10:00 AM ET (New York).

      To access the live conference call, please dial one of the following numbers:
      +45 32 72 80 18 Denmark
      +44 (0) 1452 555 131 UK
      +1 866 682 8490 USA
      Access code 88916362

      Following the conference call, a recording will be available on the company's website www.veloxis.com. A presentation will be available on Veloxis' website (under 'Investors').


      Financial Highlights













      DKK'000

      2014

      2013

      2012

      2011

      2010








      Income Statement






      Revenue

      123,395

      38,148

      6,868

      -

      1,496

      Production costs

      (3,247)

      -

      -

      -

      -

      Gross profit

      120,148

      38,148

      6,868

      -

      1,496

      Sales and marketing costs

      (41,278)

      -

      -

      -

      -

      Research and development costs

      (90,111)

      (146,512)

      (210,739)

      (222,053)

      (210,426)

      Administrative expenses

      (47,363)

      (27,771)

      (36,889)

      (47,814)

      (52,198)

      Operating result before restructuring cost

      (58,604)

      (136,135)

      (240,760)

      (269,867)

      (261,128)

      Restructuring cost

      -

      -

      (21,462)

      -

      (10,894)

      Operating result

      (58,604)

      (136,135)

      (262,222)

      (269,867)

      (272,022)

      Net financial income / (expenses)

      20,903

      (4,426)

      (850)

      16,048

      (759)

      Result before tax

      (37,701)

      (140,561)

      (263,072)

      (253,819)

      (272,781)

      Tax for the period

      1,382

      1,250

      363

      1,193

      (1,425)

      Net result for the period

      (36,319)

      (139,311)

      (262,709)

      (252,626)

      (274,206)








      Statement of Financial Position






      Cash and cash equivalents

      270,434

      328,652

      496,834

      297,727

      531,519

      Total assets

      293,723

      348,863

      509,271

      320,927

      562,906

      Share capital

      166,300

      166,057

      165,932

      452,543

      452,543

      Total equity

      253,248

      279,042

      409,737

      255,900

      498,238

      Investment in property, plant and equipment

      1,805

      1,055

      260

      2,981

      2,583








      Cash Flow Statement






      Cash flow from operating activities

      (77,243)

      (157,747)

      (205,870)

      (234,637)

      (238,148)

      Cash flow from investing activities

      (2,547)

      (1,055)

      169,712

      (169,778)

      (2,658)

      Cash flow from financing activities

      989

      (3,227)

      404,304

      (5,948)

      440,014

      Cash and cash equivalents at period end

      270,434

      328,652

      496,834

      297,727

      531,519








      Financial Ratios






      Basic and diluted EPS (DKK)

      (0.02)

      (0.08)

      (0.43)

      (0.56)

      (2.84)

      Weighted average number of shares

      1,662,266,639

      1,660,353,248

      607,511,489

      452,542,480

      96,707,708

      Average number of employees (FTEs)

      26

      26

      48

      52

      59

      Assets/equity

      1.16

      1.25

      1.24

      1.25

      1.13

      Share price

      1.15

      0.70

      0.34

      0.83

      1.31

      Fourth Quarter 2014 Highlights

      • Sales and marketing cost were realized at DKK 17.2 million compared to DKK 0 million in same period in 2013, and DKK 10.4 million in the previous quarter.
      • Research and development cost were realized at DKK 19.7 million compared to DKK 29.5 million in same period in 2013, and DKK 19.4 million in the previous quarter.
      • Administrative expenses were realized at DKK 19.4 million compared to DKK 6.5 million in same period in 2013, and DKK 10.3 million in the previous quarter.
      • Operating result amounted to a loss of DKK 56.3 million, while net result was realized at a loss of DKK 49.2 million.

      Financial Highlights








      Quarterly Numbers in DKK




















      Q4

      Q3

      Q2

      Q1

      Q4

      Q3

      Q2

      Q1



      2014

      2014

      2014

      2014

      2013

      2013

      2013

      2013



      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000

      DKK'000











      Income Statement









      Revenue

      3,214

      95,769

      12,206

      12,206

      12,206

      12,206

      6,868

      6,868

      Production costs

      (3,247)

      -

      -

      -

      -

      -

      -

      -

      Gross profit

      (33)

      95,769

      12,206

      12,206

      12,206

      12,206

      6,868

      6,868

      Sales and marketing costs

      (17,246)

      (10,378)

      (13,653)

      -

      -

      -

      -

      -

      Research and development costs

      (19,677)

      (19,391)

      (24,420)

      (26,624)

      (29,546)

      (35,247)

      (42,772)

      (38,947)

      Administrative expenses

      (19,375)

      (10,256)

      (9,983)

      (7,749)

      (6,457)

      (6,703)

      (6,834)

      (7,777)

      Operating result

      (56,331)

      55,744

      (35,850)

      (22,167)

      (23,797)

      (29,744)

      (42,738)

      (39,856)

      Net financial income / (expenses)

      5,666

      13,332

      1,228

      677

      (1,425)

      (4,655)

      (2,253)

      3,907

      Result before tax

      (50,665)

      69,076

      (34,622)

      (21,490)

      (25,222)

      (34,399)

      (44,991)

      (35,949)

      Tax for the period

      1,488

      (3,095)

      1,495

      1,494

      522

      242

      241

      244

      Net result for the period

      (49,177)

      65,981

      (33,127)

      (19,996)

      (24,700)

      (34,157)

      (44,750)

      (35,704)











      Statement of financial position









      Cash and cash equivalents

      270,434

      310,571

      264,240

      296,237

      328,652

      380,179

      399,743

      456,216

      Total assets

      293,723

      330,127

      276,493

      305,373

      348,863

      388,982

      409,371

      465,939

      Share capital

      166,300

      166,300

      166,252

      166,252

      166,057

      166,057

      166,057

      166,057

      Total equity

      253,248

      300,456

      231,649

      261,538

      279,042

      302,307

      334,686

      377,276

      Investment in property,









      plant and equipment

      1,149

      540

      (169)

      285

      1,055

      -

      -

      -











      Cash Flow Statement









      Cash flow from operating activities

      (42,139)

      32,023

      (33,577)

      (33,550)

      (47,417)

      (14,040)

      (51,165)

      (45,125)

      Cash flow from investing activities

      (1,891)

      (540)

      169

      (285)

      (1,055)

      -

      -

      -

      Cash flow from financing activities

      -

      304

      -

      684

      (319)

      (401)

      (2,555)

      48

      Cash and cash equivalents









      at period end

      270,434

      310,571

      264,240

      296,237

      328,652

      380,179

      399,743

      456,216











      Financial Ratios









      Basic and diluted EPS

      (0.03)

      0.04

      (0.02)

      (0.01)

      (0.01)

      (0.02)

      (0.03)

      (0.02)

      Weighted average number of shares

      1,662,997,314

      1,662,680,554

      1,662,527,283

      1,660,833,074

      1,660,572,426

      1,660,572,426

      1,660,572,426

      1,659,683,537

      Average number of employees (FTEs)

      31

      28

      23

      22

      23

      26

      27

      29

      Assets/equity

      1.16

      1.10

      1.19

      1.17

      1.25

      1.29

      1.22

      1.24

      Outlook for 2015
      Veloxis is expecting an operating loss of DKK 200 - 240 million compared to the realized operating loss of DKK 59 million in 2014. Net loss is expected to be in the range of DKK 195 - 235 million compared to the net loss of DKK 36 million in 2014. As of 31 December 2014, the Company's cash position equaled DKK 270 million and the Company's 31 December 2015 cash position is expected to be in the range of DKK 55 - 95 million.

      The above estimates are assuming launch of Envarsus® XR in the US in the second half of 2015. The outlook is therefore subject to possible changes primarily related to the timing and outcome of the ongoing lawsuit regarding approval of Envarsus® XR.

      Management is focused on securing additional funds beyond 2015 by either partner agreements, debt or equity, or a mix thereof.

      Important events following the balance sheet date
      13 January, Veloxis announced that it has received notice from the FDA stating that FDA continues to take the position that the exclusivity for Astagraf XL should require delay in the formal approval of Envarsus® XR.

      For more information, please contact:


      Veloxis Pharmaceuticals A/S


      Bill Polvino                             

      Johnny Stilou

      President & CEO                     

      EVP, Chief Financial Officer

      Phone: +1 732 321 3202           

      Phone: +45 3053 3364

      Email: [email protected]            

      Email: [email protected]

      The forward looking statements and targets contained herein are based on the current view and assumptions of the Executive Management and the Board of Directors of Veloxis Pharmaceuticals A/S. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Veloxis Pharmaceuticals A/S expressly disclaim any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this interim report to reflect any change in events, conditions, assumptions, or circulations on which any such statements are based unless  required by applicable law.

      About Envarsus®
      Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after organ transplantation. Envarsus® (tacrolimus prolonged-release tablets) has received marketing authorization in the EU for prophylaxis of organ rejection in kidney and liver transplant recipients. In the US, Envarsus®, known as Envarsus® XR (tacrolimus extended-release tablets), has received Tentative Approval as a once-daily tablet version of tacrolimus for prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.  Envarsus® XR has received orphan drug designation in the U.S. Veloxis plans to commercialize Envarsus® XR in the US through its own sales force and in the EU through its partnership with Chiesi Farmaceutici SpA. 

      About Veloxis Pharmaceuticals
      Based in Horsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

      For further information, please visit www.veloxis.com.

      SOURCE Veloxis Pharmaceuticals A/S

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.